Compare OSPN & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSPN | SLDB |
|---|---|---|
| Founded | 1991 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 576.4M | 464.1M |
| IPO Year | 1998 | 2018 |
| Metric | OSPN | SLDB |
|---|---|---|
| Price | $12.33 | $5.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $17.00 | $14.82 |
| AVG Volume (30 Days) | 591.9K | ★ 1.1M |
| Earning Date | 10-30-2025 | 11-03-2025 |
| Dividend Yield | ★ 3.90% | N/A |
| EPS Growth | ★ 99.92 | N/A |
| EPS | ★ 1.49 | N/A |
| Revenue | ★ $241,436,000.00 | N/A |
| Revenue This Year | $1.91 | N/A |
| Revenue Next Year | $3.49 | N/A |
| P/E Ratio | $8.27 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.00 | $2.41 |
| 52 Week High | $20.37 | $7.37 |
| Indicator | OSPN | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 41.52 | 64.94 |
| Support Level | $12.05 | $4.92 |
| Resistance Level | $12.55 | $5.45 |
| Average True Range (ATR) | 0.36 | 0.36 |
| MACD | 0.14 | 0.16 |
| Stochastic Oscillator | 59.67 | 99.16 |
OneSpan Inc is a provider of information technology security solutions for banking and financial services and application security markets. Its solutions secure and manage access to digital assets and protect online transactions, via mobile devices and in-person. Authentication and anti-fraud solutions are the organization's primary product offerings and include multifactor authentication and virtual private network access capabilities. The company derives revenues from hardware and license fees, maintenance and support fees, and subscription fees. A large majority of the firm's revenue is generated in Europe, the Middle East, and Africa, and the rest in the United States and Asia-Pacific region.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.